Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From argenx N.V.
The launch of efgartigimod at the end of 2021 is very much Argenx's focus now that J&J is terminating their alliance for the anti-CD70 antibody cusatuzumab for acute myeloid leukemia "in consideration of the evolving standard of care" for the disease.
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.
Public Company Edition: The Nasdaq Biotechnology Index appears to be in recovery from an earlier slide, but still has ground to make up. Also, Jazz sold $1.5bn worth of notes and Zai Lab closed an $823.9m follow-on offering.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
- Large Molecule
- Other Names / Subsidiaries
- arGEN-X N.V.